{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:45:04Z","timestamp":1771022704913,"version":"3.50.1"},"reference-count":27,"publisher":"Galenos Yayinevi","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jcrpe"],"DOI":"10.4274\/jcrpe.galenos.2021.2020.0287","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T10:33:45Z","timestamp":1617014025000},"page":"344-349","source":"Crossref","is-referenced-by-count":7,"title":["Left Ventricular Hypertrophy in Patients with X-Linked Hypophosphataemia"],"prefix":"10.4274","volume":"14","author":[{"given":"Ana","family":"Castellano-Martinez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Acu\u00f1as-soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Roldan-cano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moises","family":"Rodriguez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","unstructured":"1. Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, Wicart P, Bockenhauer D, Santos F, Levtchenko E, Harvengt P, Kirchhoff M, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenicky P, Rejnmark L, Linglart A. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 2019;15:435-455.","journal-title":"Nat Rev Nephrol"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Fukumoto S. FGF23-related hypophosphatemic rickets\/osteomalacia: diagnosis and new treatment. J Mol Endocrinol 2021;66:R57-R65.","DOI":"10.1530\/JME-20-0089"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Giralt M, Chocron S, Ferrer R, Ariceta G. Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia. Pediatr Nephrol 2021;36:1025-1028. Epub 2021 Jan 25.","DOI":"10.1007\/s00467-020-04906-8"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Dahir K, Roberts MS, Krolczyk S, Simmons JH. X-Linked Hypophosphatemia: A New Era in Management. J Endocr Soc 2020;4:bvaa151.","DOI":"10.1210\/jendso\/bvaa151"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 2014;10:268-278. Epub 2014 Apr 1","DOI":"10.1038\/nrneph.2014.49"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1530\/EC-20-0291","article-title":"Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations","volume":"9","author":"Padidela","year":"2020","unstructured":"6. Padidela R, Cheung MS, Saraff V, Dharmaraj P. Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations. Endocr Connect 2020;9:1051-1056.","journal-title":"Endocr Connect"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fped.2020.00048","article-title":"Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia","volume":"8","author":"Mart\u00edn Ramos","year":"2020","unstructured":"7. Mart\u00edn Ramos S, Gil-Calvo M, Rold\u00e1n V, Castellano Mart\u00ednez A, Santos F. Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia. Front Pediatr 2020;8:48.","journal-title":"Front Pediatr"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1530\/EJE-20-0275","article-title":"Validation of a next-generation sequencing (NGS) panel to improve the diagnosis of X-linked hypophosphataemia (XLH) and other genetic disorders of renal phosphate wasting","volume":"183","author":"Thiele","year":"2020","unstructured":"8. Thiele S, Werner R, Stubbe A, Hiort O, Hoeppner W. Validation of a next-generation sequencing (NGS) panel to improve the diagnosis of X-linked hypophosphataemia (XLH) and other genetic disorders of renal phosphate wasting. Eur J Endocrinol 2020;183:497-504.","journal-title":"Eur J Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.echo.2006.06.006","article-title":"Left ventricular Tei index in children: comparison of tissue Doppler imaging, pulsed wave Doppler, and M-mode echocardiography normal values","volume":"19","author":"Cui","year":"2006","unstructured":"9. Cui W, Roberson DA. Left ventricular Tei index in children: comparison of tissue Doppler imaging, pulsed wave Doppler, and M-mode echocardiography normal values. J Am Soc Echocardiogr 2006;19:1438-1445.","journal-title":"J Am Soc Echocardiogr"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1161\/01.CIR.92.11.3249","article-title":"Statistical, biological, and clinical significance","volume":"92","author":"Daniels","year":"1995","unstructured":"10. Daniels SR, Kimball TR, Morrison JA, Khoury P, Witt S, Meyer RA. Effect of lean body mass, fat mass, blood pressure, and sexual maturation on left ventricular mass in children and adolescents. Statistical, biological, and clinical significance. Circulation 1995;92:3249-3254.","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM; SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017;140:e20171904. Epub 2017 Aug 21","DOI":"10.1542\/peds.2017-3035"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Khoury PR, Mitsnefes M, Daniels SR, Kimball TR. Age-specific reference intervals for indexed left ventricular mass in children. J Am Soc Echocardiogr 2009;22:709-714. Epub 2009 May 7","DOI":"10.1016\/j.echo.2009.03.003"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Gidding SS. Assessment of Left Ventricular Mass in Children and Adolescents: Current Status. J Pediatr 2016;170:12-14. Epub 2015 Dec 31","DOI":"10.1016\/j.jpeds.2015.12.042"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Chinali M, Emma F, Esposito C, Rinelli G, Franceschini A, Doyon A, Raimondi F, Pongiglione G, Schaefer F, Matteucci MC. Left Ventricular Mass Indexing in Infants, Children, and Adolescents: A Simplified Approach for the Identification of Left Ventricular Hypertrophy in Clinical Practice. J Pediatr 2016;170:193-198. Epub 2015 Dec 6","DOI":"10.1016\/j.jpeds.2015.10.085"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Foster BJ, Khoury PR, Kimball TR, Mackie AS, Mitsnefes M. New Reference Centiles for Left Ventricular Mass Relative to Lean Body Mass in Children. J Am Soc Echocardiogr 2016;29:441-447. Epub 2016 Feb 3","DOI":"10.1016\/j.echo.2015.12.011"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Foster BJ, Mackie AS, Mitsnefes M, Ali H, Mamber S, Colan SD. A novel method of expressing left ventricular mass relative to body size in children. Circulation 2008;117:2769-2775. Epub 2008 May 19","DOI":"10.1161\/CIRCULATIONAHA.107.741157"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Pettersen MD, Du W, Skeens ME, Humes RA. Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr 2008;21:922-934. Epub 2008 Apr 11","DOI":"10.1016\/j.echo.2008.02.006"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Takashi Y, Kinoshita Y, Hori M, Ito N, Taguchi M, Fukumoto S. Patients with FGF23-related hypophosphatemic rickets\/osteomalacia do not present with left ventricular hypertrophy. Endocr Res 2017;42:132-137. Epub 2016 Oct 18","DOI":"10.1080\/07435800.2016.1242604"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Pastor-Arroyo EM, Gehring N, Krudewig C, Costantino S, Bettoni C, Kn\u00f6pfel T, Sabrautzki S, Lorenz-Depiereux B, Pastor J, Strom TM, Hrab\u011b de Angelis M, Camici GG, Paneni F, Wagner CA, Rubio-Aliaga I. The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk. Kidney Int 2018;94:49-59. Epub 2018 May 5","DOI":"10.1016\/j.kint.2018.02.017"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1210\/en.2018-00174","article-title":"Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH","volume":"159","author":"Liu","year":"2018","unstructured":"20. Liu ES, Thoonen R, Petit E, Yu B, Buys ES, Scherrer-Crosbie M, Demay MB. Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH. Endocrinology 2018;159:2165-2172.","journal-title":"Endocrinology"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Hern\u00e1ndez-Fr\u00edas O, Gil-Pe\u00f1a H, P\u00e9rez-Rold\u00e1n JM, Gonz\u00e1lez-Sanchez S, Ariceta G, Chocr\u00f3n S, Loza R, de la Cerda Ojeda F, Madariaga L, Vergara I, Fern\u00e1ndez-Fern\u00e1ndez M, Ferrando-Monle\u00f3n S, Ant\u00f3n-Gamero M, Fern\u00e1ndez-Maseda \u00c1, Luis-Yanes MI, Santos F. Risk of cardiovascular involvement in pediatric patients with X-linked hypophosphatemia. Pediatr Nephrol 2019;34:1077-1086. Epub 2019 Jan 4","DOI":"10.1007\/s00467-018-4180-3"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Guti\u00e9rrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408. Epub 2011 Oct 10","DOI":"10.1172\/JCI46122"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Okamoto Y, Fujita S, Morita H, Kizawa S, Ito T, Sakane K, Sohmiya K, Hoshiga M, Ishizaka N. Association between circulating FGF23, \u03b1-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction. Heart Vessels 2016;31:66-73. Epub 2014 Sep 16","DOI":"10.1007\/s00380-014-0581-9"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1210\/jcem.82.8.4181","article-title":"Cardiovascular abnormalities in patients with X-linked hypophosphatemia","volume":"82","author":"Nehgme","year":"1997","unstructured":"24. Nehgme R, Fahey JT, Smith C, Carpenter TO. Cardiovascular abnormalities in patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 1997;82:2450-2454.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11906-017-0791-5","article-title":"Ambulatory Blood Pressure Monitoring in Children and Adolescents: a Review of Recent Literature and New Guidelines","volume":"19","author":"Macumber","year":"2017","unstructured":"25. Macumber I. Ambulatory Blood Pressure Monitoring in Children and Adolescents: a Review of Recent Literature and New Guidelines. Curr Hypertens Rep 2017;19:96.","journal-title":"Curr Hypertens Rep"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Haffner D, Leifheit-Nestler M. Extrarenal effects of FGF23. Pediatr Nephrol 2017;32:753-765. Epub 2016 Oct 4","DOI":"10.1007\/s00467-016-3505-3"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Mitsnefes MM, Betoko A, Schneider MF, Salusky IB, Wolf MS, J\u00fcppner H, Warady BA, Furth SL, Portale AA. FGF23 and Left Ventricular Hypertrophy in Children with CKD. Clin J Am Soc Nephrol 2018;13:45-52. Epub 2017 Oct 12","DOI":"10.2215\/CJN.02110217"}],"container-title":["Journal of Clinical Research in Pediatric Endocrinology"],"original-title":[],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T13:05:41Z","timestamp":1721999141000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcrpe.org\/jvi.aspx?un=JCRPE-65002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,8,24]]}},"URL":"https:\/\/doi.org\/10.4274\/jcrpe.galenos.2021.2020.0287","relation":{},"ISSN":["1308-5727","1308-5735"],"issn-type":[{"value":"1308-5727","type":"print"},{"value":"1308-5735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]}}}